Relief Therapeutics Holding SA (RLFTF)
OTCMKTS · Delayed Price · Currency is USD
2.940
-0.260 (-8.13%)
Aug 5, 2025, 2:57 PM EDT
ShockWave Medical Revenue
In the year 2024, Relief Therapeutics Holding had annual revenue of 8.42M CHF with 39.52% growth. Relief Therapeutics Holding had revenue of 3.01M in the half year ending December 31, 2023, a decrease of -9.36%.
Revenue
8.42M CHF
Revenue Growth
+39.52%
P/S Ratio
4.14
Revenue / Employee
271.52K CHF
Employees
31
Market Cap
38.44M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.42M | 2.38M | 39.52% |
Dec 31, 2023 | 6.03M | -48.00K | -0.79% |
Dec 31, 2022 | 6.08M | 2.76M | 83.11% |
Dec 31, 2021 | 3.32M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
BioStem Technologies | 332.45M |
Relief Therapeutics Holding News
- 8 days ago - Relief Therapeutics reports proposed business combination with NeuroX - Seeking Alpha
- 8 days ago - Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze - Accesswire
- 6 weeks ago - Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 - Accesswire
- 7 weeks ago - Relief Therapeutics Announces Results of Annual General Meeting - Accesswire
- 2 months ago - Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 - Accesswire
- 2 months ago - Relief Therapeutics Publishes 2025 Annual General Meeting Agenda - Accesswire
- 4 months ago - Relief Therapeutics Holding GAAP EPS of -CHF 1.37, revenue of CHF 9.83B - Seeking Alpha
- 4 months ago - Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update - Accesswire